Godavari Drugs Limited operates a manufacturing facility in Nanded, Maharashtra, India, specializing in the production of Active Pharmaceutical Ingredients (API) and drug intermediates. Its flagship product, Sulphamethoxazole (SMX), is a widely sought-after antibacterial medication with a strong export market.
Established in December 1987, the company boasts multiple production blocks for API's, drug intermediates, and fine chemicals. Over time, it has expanded its SMX capacity from 540 to 720 tons per annum (tpa), while also diversifying into related products like Sulphamethoxide (capacity: 450 tpa), Diethyl Oxalate (capacity: 750 tpa), and Trimethoprim (capacity: 144 tpa).
The move into Trimethoprim (TMP) production is strategically advantageous, given its synergistic use with SMX in treating various infections. Additionally, backward integration into the production of Sulphamethoxide (SMO) and Diethyl Oxalate (DEO) promises to enhance value addition for the company.
In 2000, Godavari Drugs Limited introduced 'Pyrazyamide' to the market, which has been well-received. As a result, the company plans to increase Pyrazyamide's capacity to 180 TPA and is also finalizing plans for other products like Cislactum, an intermediate used in producing Diltiazem, an anti-anginal drug.
Leveraging its expertise in chemistry and process development, the company seamlessly transitions from laboratory-scale to pilot-scale and finally to commercial-scale manufacturing, adhering to cGMP requirements throughout. This integration of chemical knowledge with engineering capabilities and robust analytical support enables Godavari Drugs to develop, scale up, and manufacture products efficiently across all stages.
Established in December 1987, the company boasts multiple production blocks for API's, drug intermediates, and fine chemicals. Over time, it has expanded its SMX capacity from 540 to 720 tons per annum (tpa), while also diversifying into related products like Sulphamethoxide (capacity: 450 tpa), Diethyl Oxalate (capacity: 750 tpa), and Trimethoprim (capacity: 144 tpa).
The move into Trimethoprim (TMP) production is strategically advantageous, given its synergistic use with SMX in treating various infections. Additionally, backward integration into the production of Sulphamethoxide (SMO) and Diethyl Oxalate (DEO) promises to enhance value addition for the company.
In 2000, Godavari Drugs Limited introduced 'Pyrazyamide' to the market, which has been well-received. As a result, the company plans to increase Pyrazyamide's capacity to 180 TPA and is also finalizing plans for other products like Cislactum, an intermediate used in producing Diltiazem, an anti-anginal drug.
Leveraging its expertise in chemistry and process development, the company seamlessly transitions from laboratory-scale to pilot-scale and finally to commercial-scale manufacturing, adhering to cGMP requirements throughout. This integration of chemical knowledge with engineering capabilities and robust analytical support enables Godavari Drugs to develop, scale up, and manufacture products efficiently across all stages.
